Future cardiology最新文献_第2页

Acute aortic regurgitation: a call for urgent intervention.

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-05 DOI: 10.1080/14796678.2025.2472551

Venugopal Menon, Alexandra Hall

引用次数: 0

First experience with a new tool for automatic mapping of fragmented signals in a case report of cardioneuroablation.

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-09 DOI: 10.1080/14796678.2025.2476313

Helge Haarmann, Besir Hasan, Nibras Soubh, Eva Rasenack, Simon Schlögl, Markus Zabel, Leonard Bergau

引用次数: 0

Introducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review.

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1080/14796678.2025.2476351

Maisha Maliha, Vikyath Satish, Kuan Yu Chi, Amrin Kharawala, Sanjana Nagraj, Tinatin Saralidze, Nathaniel Abittan, Natalia Nazarenko, Gal Rubinstein, Riya Patel, Seth I Sokol, Robert T Faillaice, Leonidas Palaiodimos

{"title":"Introducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review.","authors":"Maisha Maliha, Vikyath Satish, Kuan Yu Chi, Amrin Kharawala, Sanjana Nagraj, Tinatin Saralidze, Nathaniel Abittan, Natalia Nazarenko, Gal Rubinstein, Riya Patel, Seth I Sokol, Robert T Faillaice, Leonidas Palaiodimos","doi":"10.1080/14796678.2025.2476351","DOIUrl":"10.1080/14796678.2025.2476351","url":null,"abstract":"Introduction: Nonbacterial thrombotic endocarditis (NBTE) involves vegetations on heart valves without active bloodstream infection. The AngioVac device, a vacuum-based aspiration system commonly used for infective endocarditis, has potential in managing NBTE, particularly in patients unsuitable for surgery. This study systematically reviews the literature to evaluate AngioVac's effectiveness in reducing vegetations in NBTE.Methods: A systematic literature review was conducted using PubMed, Embase, Cochrane, and Web of Science databases through February 2024. Primary outcome was procedural success, defined as a ≥ 50% reduction in vegetation size on transesophageal echocardiogram. Secondary outcomes included in-hospital mortality, hospital stay length, and procedural complications.Results: Out of 38 identified articles, 4 case reports met inclusion criteria. Patients were male with a median age of 60 years, and NBTE was associated with conditions such as lung adenocarcinoma, end-stage renal disease, and antiphospholipid syndrome. The mitral valve was the most commonly affected site. AngioVac achieved 100% procedural success, with no complications or in-hospital mortality. The average hospital stay was 2 days. Follow-up revealed one patient alive at 2 months, one deceased at 3 months and no data for two patients.Conclusion: AngioVac is a promising tool for safely reducing vegetations in NBTE, especially for high-risk surgical candidates.The study design and protocol are registered with PROSPERO International Prospective Register of Systematic Reviews (registration number CRD42024505295).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"305-313"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment options for heart failure in individuals with overweight or obesity: a review.

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-18 DOI: 10.1080/14796678.2025.2479378

Athina Nasoufidou, Panagiotis Stachteas, Paschalis Karakasis, Christos Kofos, Efstratios Karagiannidis, Aleksandra Klisic, Djordje S Popovic, Theocharis Koufakis, Nikolaos Fragakis, Dimitrios Patoulias

{"title":"Treatment options for heart failure in individuals with overweight or obesity: a review.","authors":"Athina Nasoufidou, Panagiotis Stachteas, Paschalis Karakasis, Christos Kofos, Efstratios Karagiannidis, Aleksandra Klisic, Djordje S Popovic, Theocharis Koufakis, Nikolaos Fragakis, Dimitrios Patoulias","doi":"10.1080/14796678.2025.2479378","DOIUrl":"10.1080/14796678.2025.2479378","url":null,"abstract":"Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity and mortality. Obesity is not only a risk-factor for heart failure, but also complicates its management, by distinctive pathophysiological mechanisms and cumulative comorbidities, requiring tailored treatment plan. To present current treatment options for heart failure in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, and the management of related comorbidities. We conducted a comprehensive literature review regarding the results of heart failure treatments in individuals with overweight/obesity, including cornerstone interventions as well as emerging therapeutic options. Specific drug classes, including angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, have demonstrated consistent efficacy in heart failure irrespective of body mass index, while diuretics remain a key for fluid management. Glucagon-like peptide-1 receptor agonists have shown promising results in improving relevant outcomes and warrant further research. Non-pharmacological approaches, including weight-loss strategies and lifestyle modifications, have shown to improve symptoms, exercise tolerance and quality of life. Managing heart failure in individuals with overweight/obesity requires a multidisciplinary, individualized approach integrating pharmacological and non-pharmacological options. Emerging therapies and preventive strategies arise to address the unique challenges in this population and provide improved outcomes.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"315-329"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing cerebrovascular events in patients undergoing TAVR: the current and future landscape.

IF 1.6

Future cardiology Pub Date : 2025-03-31 DOI: 10.1080/14796678.2025.2484961

Saadullah H Ahmed, Amit N Vora, Tayyab Shah, Alexandra J Lansky

引用次数: 0

Do gender differences persist in ICD implantation in patients with acute on chronic heart failure?

IF 1.6

Future cardiology Pub Date : 2025-03-30 DOI: 10.1080/14796678.2025.2484958

Jude ElSaygh, Laura Bradel, Kevin Pink, Lu Chen, Jonathan Arnedo, Bharath Reddy, Brian Wong, Jeremy Berman, Stephen J Peterson, Wilber S Aronow, Gioia Turitto

{"title":"Do gender differences persist in ICD implantation in patients with acute on chronic heart failure?","authors":"Jude ElSaygh, Laura Bradel, Kevin Pink, Lu Chen, Jonathan Arnedo, Bharath Reddy, Brian Wong, Jeremy Berman, Stephen J Peterson, Wilber S Aronow, Gioia Turitto","doi":"10.1080/14796678.2025.2484958","DOIUrl":"https://doi.org/10.1080/14796678.2025.2484958","url":null,"abstract":"Background: Implantable Cardiac Defibrillators (ICDs) prolong survival in patients with heart failure with reduced ejection fraction (HFrEF). Despite strong data suggesting their benefit, there is concern for disparities related to ICD implantation rates.Methods: A retrospective analysis of 551 patients admitted to a single tertiary institution from June 2020 to May 2023, who met the guideline criteria for ICD implantation for primary prevention of sudden cardiac death, was carried out.Results: Our population constituted of 56% African Americans, 20% Caucasians, 1% Asians and 2% Native Americans. Of those patients, 47% (157/337) of males and 33% (71/213) of females underwent ICD implantation before discharge, creating a statistically significant gender difference at p = 0.007. Patients aged 50 or greater (218/509) were more likely to receive an ICD compared to younger patients (10/41) at p = 0.000. Of those offered an ICD, 46% deferred to outpatient, 30% refused, and 8% of patient had history of noncompliance, were medically unstable, or were undecided.Conclusion: Females and younger patients were less likely to have an ICD at discharge. Despite strong recommendations for ICD implantation in eligible patients, most patients did not receive an ICD. This study showcases the limited access to care and highlights potential avenues of improvement.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-6"},"PeriodicalIF":1.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction.

IF 1.6

Future cardiology Pub Date : 2025-03-26 DOI: 10.1080/14796678.2025.2483603

引用次数: 0

Left atrial appendage occlusion in atrial fibrillation: shaping the future of stroke prevention.

IF 1.6

Future cardiology Pub Date : 2025-03-26 DOI: 10.1080/14796678.2025.2484964

Andreas Mitsis, Christos Eftychiou, Athanasios Samaras, Apostolos Tzikas, Nikolaos Fragakis, George Kassimis

{"title":"Left atrial appendage occlusion in atrial fibrillation: shaping the future of stroke prevention.","authors":"Andreas Mitsis, Christos Eftychiou, Athanasios Samaras, Apostolos Tzikas, Nikolaos Fragakis, George Kassimis","doi":"10.1080/14796678.2025.2484964","DOIUrl":"10.1080/14796678.2025.2484964","url":null,"abstract":"Atrial fibrillation (AF) is the most common cardiac arrhythmia, significantly increasing the risk of thromboembolic events, particularly ischemic stroke. The left atrial appendage (LAA) is the predominant site of thrombus formation in patients with AF, making it a crucial target for stroke prevention strategies. Left atrial appendage occlusion (LAAO) has emerged as an important therapeutic alternative to oral anticoagulation, particularly in patients with contraindications to long-term anticoagulant therapy. This review examines the role of LAAO in AF management, discussing current indications, patient selection, procedural techniques, and clinical outcomes. We also explore the latest evidence from major clinical trials and real-world studies, highlighting the efficacy and safety of LAAO compared to standard anticoagulation. Additionally, we consider the unresolved questions and the potential future directions for this intervention, including emerging technologies and the integration of LAAO into broader AF management protocols. Our review underscores the growing importance of LAAO in reducing thromboembolic risk in AF patients, particularly those unable to tolerate traditional anticoagulation, and offers insights into the ongoing evolution of this treatment modality in clinical practice.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-14"},"PeriodicalIF":1.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Observational protocol on neuropsychological disorders in cardiovascular disease for holistic prevention and treatment.

IF 1.6

Future cardiology Pub Date : 2025-03-21 DOI: 10.1080/14796678.2025.2483155

Irene Cappadona, Augusto Ielo, Maria Pagano, Anna Anselmo, Giuseppe Micali, Fabio Mauro Giambò, Antonio Duca, Piercataldo D'Aleo, Daniela Costanzo, Giuseppa Carcione, Claudio Dispenzieri, Francesco Speciale, Placido Bramanti, Alessia Bramanti, Marina Garofano, Francesco Corallo

{"title":"Observational protocol on neuropsychological disorders in cardiovascular disease for holistic prevention and treatment.","authors":"Irene Cappadona, Augusto Ielo, Maria Pagano, Anna Anselmo, Giuseppe Micali, Fabio Mauro Giambò, Antonio Duca, Piercataldo D'Aleo, Daniela Costanzo, Giuseppa Carcione, Claudio Dispenzieri, Francesco Speciale, Placido Bramanti, Alessia Bramanti, Marina Garofano, Francesco Corallo","doi":"10.1080/14796678.2025.2483155","DOIUrl":"https://doi.org/10.1080/14796678.2025.2483155","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. In view of the close correlation between the functions of the body, which cannot be examined in a piecemeal manner but as an integrated system, a holistic approach allows for a comprehensive assessment of the patient. Our study aims to (i) examine the connection between CVD and cognitive deficits; (ii) examine the presence of anxiety and depression; (iii) evaluate the presence of dysphagia, pneumophonic coordination disorders, respiratory and sleep disorders; (iv) analyze the impact of CVD on the caregiver; and (v) evaluate the effectiveness of psychoeducational intervention. At least 218 patients will participate in the survey. At T0, they will undergo neuropsychological, psychological and associated clinical condition assessment through standardized tests. In addition, at least one psychoeducation meeting will be held. After 6 months (T1), the same tests will be repeated, and the effectiveness of psychoeducation will be evaluated. Assessment of associated disorders will provide a comprehensive view of the patient. In addition, it will be observed how psychoeducational intervention can make changes on general well-being. Comprehensive, multi-step observation allows for identification of risk factors, tailoring of treatment, and prevention of future complications.Clinical Trial Registration: registered on Clinicaltrials.gov (ID: NCT06413823).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future role of biomarkers in the monitoring and prognosis of coronary artery disease.

IF 1.6

Future cardiology Pub Date : 2025-03-10 DOI: 10.1080/14796678.2025.2477947

Vikrant Rai

引用次数: 0